close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Beckley Psytech

News headline image
First Patient Dosed in Beckley Psytech’s Phase IIa Study of BPL-003 for Treatment Resistant Depression
From Beckley Psytech
Via Business Wire
News headline image
Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003, a Novel Benzoate Formulation of 5-MeO-DMT, for Treatment Resistant Depression
From Beckley Psytech
Via Business Wire
News headline image
Beckley Psytech Successfully Completes Phase I Clinical Study of Lead Candidate BPL-003, a Novel Benzoate Formulation Of 5-MeO-DMT
From Beckley Psytech
Via Business Wire
News headline image
Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101, A Novel Intravenous Formulation of Psilocin
From Beckley Psytech
Via Business Wire
News headline image
Beckley Psytech to Attend and Present at the Jefferies London Healthcare Conference – November 15-17, 2022
From Beckley Psytech
Via Business Wire
News headline image
Beckley Psytech Strengthens Pipeline and Development Team With Acquisition of Eleusis Therapeutics Limited
From Beckley Psytech
Via Business Wire
News headline image
Beckley Psytech Strengthens Senior Leadership Team With Appointment of Dr. Laura Trespidi as Chief Development Officer
From Beckley Psytech
Via Business Wire
News headline image
Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of Second Innovative Formulation of 5-MeO-DMT
From Beckley Psytech
Via Business Wire
News headline image
Beckley Psytech Announces First Cohort of Psychotherapists Have Begun Training for Treatment Resistant Depression Phase 2 Trials
From Beckley Psytech
Via Business Wire
News headline image
Beckley Psytech to attend 11th Annual LifeSci Partners Virtual Corporate Access Event
From Beckley Psytech
Via Business Wire
News headline image
Beckley Psytech to present at H.C. Wainwright 2nd Annual Psychedelics Conference and Stifel 2nd Annual Conference “The Future of Healthcare”
From Beckley Psytech
Via Business Wire
News headline image
Dr Frank Wiegand, Experienced Neuroscience Leader Joins Beckley Psytech as Chief Medical Officer
From Beckley Psytech
Via Business Wire
News headline image
Beckley Psytech to present at Jefferies 2021 London Healthcare Conference
From Beckley Psytech
Via Business Wire
News headline image
Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial Assessing Safety and Tolerability of Intranasal 5-MeO-DMT
From Beckley Psytech
Via Business Wire
News headline image
Beckley Psytech completes oversubscribed $80m (£58m) fundraise to develop portfolio of psychedelic medicine breakthroughs
From Beckley Psytech
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today